Andrew Dickinson Net Worth

The estimated Net Worth of Andrew D Dickinson is at least $18.2 Million dollars as of 10 September 2024. Mr. Dickinson owns over 3,641 units of Gilead Sciences stock worth over $11,380,245 and over the last 5 years he sold GILD stock worth over $1,228,900. In addition, he makes $5,609,470 as Chief Financial Officer and Executive Vice President at Gilead Sciences.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Dickinson GILD stock SEC Form 4 insiders trading

Andrew has made over 28 trades of the Gilead Sciences stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 3,641 units of GILD stock worth $294,703 on 10 September 2024.

The largest trade he's ever made was exercising 10,419 units of Gilead Sciences stock on 10 March 2023 worth over $843,314. On average, Andrew trades about 2,674 units every 49 days since 2019. As of 10 September 2024 he still owns at least 140,601 units of Gilead Sciences stock.

You can see the complete history of Mr. Dickinson stock trades at the bottom of the page.

Andrew Dickinson biography

Andrew D. Dickinson serves as Chief Financial Officer, Executive Vice President of the Company. Mr. Dickinson serves as Gilead’s Executive Vice President and Chief Financial Officer, responsible for the oversight of the company’s global finance, corporate development, information technology, operations and strategy organizations. Mr. Dickinson joined Gilead in 2016 and prior to his current role served as head of the company’s corporate development and strategy group. In that role, Mr. Dickinson drove all of Gilead’s licensing, partnership and acquisition transactions and guided investments into new areas. Prior to his tenure at Gilead, Mr. Dickinson was the global Co-Head of Healthcare Investment Banking at Lazard. Earlier in his career, he served as General Counsel and Vice President of Corporate Development at Myogen, Inc., which was acquired by Gilead in 2006. Mr. Dickinson received his bachelor’s degree in molecular, cellular and developmental biology from the University of Colorado at Boulder and his law degree from Loyola University of Chicago..

What is the salary of Andrew Dickinson?

As the Chief Financial Officer and Executive Vice President of Gilead Sciences, the total compensation of Andrew Dickinson at Gilead Sciences is $5,609,470. There are 3 executives at Gilead Sciences getting paid more, with Daniel O'Day having the highest compensation of $29,107,900.

How old is Andrew Dickinson?

Andrew Dickinson is 50, he's been the Chief Financial Officer and Executive Vice President of Gilead Sciences since 2019. There are 21 older and 2 younger executives at Gilead Sciences. The oldest executive at Gilead Sciences, Inc. is Richard Whitley, 74, who is the Independent Director.

What's Andrew Dickinson's mailing address?

Andrew's mailing address filed with the SEC is GILEAD SCIENCES, INC., 333 LAKESIDE DRIVE, FOSTER CITY, CA, 94404.

Insiders trading at Gilead Sciences

Over the last 22 years, insiders at Gilead Sciences have traded over $221,090,692 worth of Gilead Sciences stock and bought 30,121 units worth $1,879,767 . The most active insiders traders include John C Martin, Norbert W Bischofberger, and John F Milligan. On average, Gilead Sciences executives and independent directors trade stock every 9 days with the average trade being worth of $3,341,365. The most recent stock trade was executed by Deborah H Telman on 10 September 2024, trading 639 units of GILD stock currently worth $51,721.

What does Gilead Sciences do?

Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir.

Complete history of Mr. Dickinson stock trades at Gilead Sciences

Gilead Sciences executives and stock owners

Gilead Sciences executives and other stock owners filed with the SEC include:

• Daniel O'Day,
  Chairman of the Board, Chief Executive Officer
• Johanna Mercier,
  Chief Commercial Officer
• Daniel P. O'Day,
  Chairman & CEO
• Andrew Dickinson,
  Chief Financial Officer, Executive Vice President
• Brett Pletcher,
  Executive Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary
• Johanna Mercier,
  Chief Commercial Officer
• Dr. Merdad V. Parsey M.D., Ph.D.,
  Chief Medical Officer
• Merdad Parsey,
  Chief Medical Officer
• Brett A. Pletcher,
  Exec. VP of Corp. Affairs, Gen. Counsel & Corp. Sec.
• Andrew D. Dickinson,
  Exec. VP & CFO
• Per Wold-Olsen,
  Independent Director
• Richard Whitley,
  Independent Director
• Kelly Kramer,
  Independent Director
• Kevin Lofton,
  Lead Independent Director
• Harish Manwani,
  Independent Director
• Jacqueline Barton,
  Independent Director
• Sandra Horning,
  Independent Director
• Anthony Welters,
  Director
• Javier Rodriguez,
  Director
• Michael Quigley,
  Senior Vice President - Research Biology
• Linda Higgins,
  Senior Vice President - Head of External Innovation
• Jyoti Mehra,
  Executive Vice President of Human Resources
• Dr. Linda Slanec Higgins Ph.D.,
  Sr. VP & Head of External Innovation
• Jyoti K. Mehra,
  Exec. VP of HR
• Deborah H. Telman,
  Exec. VP of Corp. Affairs, Gen. Counsel & Corp. Sec.
• Dr. Diana M. Brainard M.D.,
  Sr. VP of HIV & Emerging Viral Infections
• Dr. Taiyin Yang,
  Exec. VP of Pharmaceutical Devel. & Manufacturing
• Jacquie Ross C.F.A.,
  VP of Investor Relations
• Diane E. Wilfong,
  Sr. VP, Corp. Controller & Chief Accounting Officer
• John Francis Cogan,
  Director
• John W Madigan,
  Director
• Robin L Washington,
  SVP, CFO
• Norbert W Bischofberger,
  SVP, Research
• James R Meyers,
  SVP Comm Ops North America
• Nicholas G Moore,
  Director
• Gayle E Wilson,
  Director
• Kevin Young,
  EVP, Commercial Operations
• Laura Hamill,
  EVP, Worldwide Commercial Ops
• Carla A Hills,
  Director
• Etienne Davignon,
  Director
• Paul Rutherford Carter,
  EVP Commercial Ops
• John C Martin,
  President and CEO
• John F Milligan,
  EVP, Chief Financial Officer
• John G Mc Hutchison,
  Chief Scientific Off/HeadR&D
• James M Denny,
  Director
• Gordon Earle Moore,
  Director
• Kristen Metza,
  SVP, Human Resources
• Gregg H Alton,
  SVP, General Counsel
• Paul Berg,
  Director
• Louis G Lange,
  EVP Cardiovascular Therapeutic
• Taiyin Yang,
  SVP, Pharm Dev & Mfg
• William A Lee,
  SVP Research and PPD
• Anthony Caracciolo,
  SVP
• Caroline Dorsa,
  SVP, Chief Financial Officer
• John J Toole,
  SVP
• George P Shultz,
  Director
• Alan Bruce Montgomery,
  SVP, Respiratory Therapeutics
• Michael K Inouye,
  SVP
• Mark L Perry,
  EVP Operations
• Cordell W Hull,
  Director
• Diane E. Wilfong,
  SVP, Controller & CAO
• Sandra Patterson,
  SVP, Controllership
• Jeffrey Bluestone,
  Director
• Deborah H Telman,
  EVP, Corporate Affairs & GC
• Ted W Love,
  Director